Bayer
Sentiment Over Time
Analysis Timeline
"Preliminary approval of a collective settlement in Missouri and anticipation of a favorable US Supreme Court ruling significantly de-risks Glyphosate litigation, causing a substantial stock increase."
"Used as an example of a company making large, problematic acquisitions and capital allocation errors."
"Reached a significant settlement regarding glyphosate claims and shows signs of operational improvement, but still faces lingering legal uncertainties which impact market sentiment."
"Stock dropped over 7% as market euphoria over a US settlement proved premature, indicating ongoing legal uncertainties."
"Referenced as another German company with a highly problematic and costly acquisition (Monsanto) in the US, used as a cautionary example."
"Stock gained significantly (nearly 8%) due to a major Glyphosate settlement, but risks related to judge approval and Supreme Court ruling remain."
"Stock made 130% return, driven by Glyphosate settlement clarity, new herbicide approval, successful pharmaceutical pipeline (Asundexian, Nubeqa, Elinzanetant), and significant management restructuring."
"Reported a research success for a drug candidate, leading to a 2% increase in its stock price."
"Has significant upside if the glyphosate litigation risk is resolved, as its parts are worth more than the current market cap; however, it remains risky."
"High-risk, high-reward turnaround fantasy based on potential legal resolutions and future pharmaceutical innovations, despite current debt and R&D challenges."
"Cited for aiming to reduce costs by two billion by working in small, self-directed teams for 90-day cycles."
"Continued its strong performance, being a top DAX mover and a best-performing stock in the previous year."
"Supreme Court wird Roundup-Fälle anhören; deutlicher Kursanstieg, positive operative Marga-Prognose."
"War Tagessieger im DAX mit fast 7% Plus, befeuert durch Hoffnung auf juristischen Durchbruch bei Glyphosatklagen."
"Aktie stieg um 5% aufgrund positiver Entwicklungen im Glyphosat-Rechtsstreit; Oberster Gerichtshof befasst sich mit dem Fall, Aktie mehr als verdoppelt in 12 Monaten."
"Aktienanstieg von über 6% nach der Ankündigung des US Supreme Courts, sich grundsätzlich mit dem Glyphosatstreit zu beschäftigen, was eine deutliche Entlastung für das Unternehmen bedeuten könnte."
"Der Supreme Court in den USA prüft einen wichtigen Fall im Glyphosatverfahren, was als gute Nachricht und wichtiger Schritt zur Eindämmung von Rechtsstreitigkeiten für das Unternehmen gewertet wird."
"Starkes Jahresplus (12% YTD, 100% Jahresperformance), zeigt Comeback-Potenzial."